MedTrace Logo

Mechanisms Underlying Metabolic Syndrome in Obesity

NCT00579813 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2017-06-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to better understand the link between obesity and diabetes or pre-diabetes.

Conditions

Interventions

DRUG

Pioglitazone

Pioglitazone 30mg for 2 weeks, then Pioglitazone 45mg for 8 weeks.

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Philip Kern

    lead OTHER

Principal Investigators

  • Philip Kern, MD · University of Kentucky

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2009-01-31
Completion
2011-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00579813 on ClinicalTrials.gov